ProMetic Closes $9.8M Private Stock Placement | GenomeWeb

ProMetic Closes $9.8M Private Stock Placement

Jun 07, 2006

NEW YORK, June 7 (GenomeWeb News) - ProMetic Life Sciences closed a private placement of 29.6 million subordinate voting shares valued at CA$10.8 million ($9.8 million) with JPMorgan and Third Point, the biopharmaceutical company said today.

The shares were priced at CA$.365 per share.

The funds will be used to develop PBI-1402, an orally active drug for the treatment of anemia in cancer patients undergoing chemotherapy, as well as for general corporate purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Embryos Edited in US

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

True Blue

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

All the Plants

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

This Week in Nature

In Nature this week: a Danish reference genome, and more.